The Brazilian experience of implementing the active pharmacovigilance of dolutegravir

Cynthia Julia Braga Batista, Renato Girade Correa, Livia Ramalho Evangelista, Karen Fleck, Leandro Silva, Francoise Renaud, Marco Vitoria, Meg Caroline Doherty, Adele Schwartz Benzaken

Research output: Contribution to journalArticle

Abstract

In 2017, the Ministry of Health Brazilian started using dolutegravir (DTG) 50 mg to all people living with HIV who began antiretroviral therapy (ART) or rescue regimens. Although DTG is thought to have better tolerability levels and a lower possibility of causing adverse reactions, it is necessary to continuously evaluate the safety profile of the drug in the population. Therefore, an active pharmacovigilance project for DTG was implemented. The objective of this study was to describe the Brazilian experience of implementing pharmacovigilance and the results obtained during the period between April and December 2017.Active pharmacovigilance was implemented through patient interviews and an online questionnaire developed in the Medication Logistics Control System (SICLOM).Of the total number of people on DTG in Brazil (79,742) 90.33% participated in the project, and 2.24% of those who participated reported adverse reactions to the drug; of those who reported adverse reactions, 73.86% were on first-line ART regimens, and 26.13% were on third-line regimens. The mean age of the patients who had adverse reactions to DTG was 39 years; 68.79% were male, and 31.21% were female. Of the adverse reactions reported, 50.39% were considered persistent. The 3 most frequent reactions were nausea (13.34%), diarrhea (9.83%), and headaches (9.23%).The Brazilian experience with this project has been deemed successful by federal and local managers, and the online tool to collect data has proved to be an important strategy for the pharmacovigilance of DTG as well as that of other drugs.

Original languageEnglish (US)
Pages (from-to)e14828
JournalMedicine
Volume98
Issue number10
DOIs
StatePublished - Mar 1 2019
Externally publishedYes

Fingerprint

Pharmacovigilance
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Nausea
Brazil
Headache
dolutegravir
Diarrhea
HIV
Interviews
Safety
Health
Therapeutics
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Batista, C. J. B., Correa, R. G., Evangelista, L. R., Fleck, K., Silva, L., Renaud, F., ... Benzaken, A. S. (2019). The Brazilian experience of implementing the active pharmacovigilance of dolutegravir. Medicine, 98(10), e14828. https://doi.org/10.1097/MD.0000000000014828

The Brazilian experience of implementing the active pharmacovigilance of dolutegravir. / Batista, Cynthia Julia Braga; Correa, Renato Girade; Evangelista, Livia Ramalho; Fleck, Karen; Silva, Leandro; Renaud, Francoise; Vitoria, Marco; Doherty, Meg Caroline; Benzaken, Adele Schwartz.

In: Medicine, Vol. 98, No. 10, 01.03.2019, p. e14828.

Research output: Contribution to journalArticle

Batista, CJB, Correa, RG, Evangelista, LR, Fleck, K, Silva, L, Renaud, F, Vitoria, M, Doherty, MC & Benzaken, AS 2019, 'The Brazilian experience of implementing the active pharmacovigilance of dolutegravir', Medicine, vol. 98, no. 10, pp. e14828. https://doi.org/10.1097/MD.0000000000014828
Batista CJB, Correa RG, Evangelista LR, Fleck K, Silva L, Renaud F et al. The Brazilian experience of implementing the active pharmacovigilance of dolutegravir. Medicine. 2019 Mar 1;98(10):e14828. https://doi.org/10.1097/MD.0000000000014828
Batista, Cynthia Julia Braga ; Correa, Renato Girade ; Evangelista, Livia Ramalho ; Fleck, Karen ; Silva, Leandro ; Renaud, Francoise ; Vitoria, Marco ; Doherty, Meg Caroline ; Benzaken, Adele Schwartz. / The Brazilian experience of implementing the active pharmacovigilance of dolutegravir. In: Medicine. 2019 ; Vol. 98, No. 10. pp. e14828.
@article{0f535cf388fe4a249e5006b91a662707,
title = "The Brazilian experience of implementing the active pharmacovigilance of dolutegravir",
abstract = "In 2017, the Ministry of Health Brazilian started using dolutegravir (DTG) 50 mg to all people living with HIV who began antiretroviral therapy (ART) or rescue regimens. Although DTG is thought to have better tolerability levels and a lower possibility of causing adverse reactions, it is necessary to continuously evaluate the safety profile of the drug in the population. Therefore, an active pharmacovigilance project for DTG was implemented. The objective of this study was to describe the Brazilian experience of implementing pharmacovigilance and the results obtained during the period between April and December 2017.Active pharmacovigilance was implemented through patient interviews and an online questionnaire developed in the Medication Logistics Control System (SICLOM).Of the total number of people on DTG in Brazil (79,742) 90.33{\%} participated in the project, and 2.24{\%} of those who participated reported adverse reactions to the drug; of those who reported adverse reactions, 73.86{\%} were on first-line ART regimens, and 26.13{\%} were on third-line regimens. The mean age of the patients who had adverse reactions to DTG was 39 years; 68.79{\%} were male, and 31.21{\%} were female. Of the adverse reactions reported, 50.39{\%} were considered persistent. The 3 most frequent reactions were nausea (13.34{\%}), diarrhea (9.83{\%}), and headaches (9.23{\%}).The Brazilian experience with this project has been deemed successful by federal and local managers, and the online tool to collect data has proved to be an important strategy for the pharmacovigilance of DTG as well as that of other drugs.",
author = "Batista, {Cynthia Julia Braga} and Correa, {Renato Girade} and Evangelista, {Livia Ramalho} and Karen Fleck and Leandro Silva and Francoise Renaud and Marco Vitoria and Doherty, {Meg Caroline} and Benzaken, {Adele Schwartz}",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/MD.0000000000014828",
language = "English (US)",
volume = "98",
pages = "e14828",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "10",

}

TY - JOUR

T1 - The Brazilian experience of implementing the active pharmacovigilance of dolutegravir

AU - Batista, Cynthia Julia Braga

AU - Correa, Renato Girade

AU - Evangelista, Livia Ramalho

AU - Fleck, Karen

AU - Silva, Leandro

AU - Renaud, Francoise

AU - Vitoria, Marco

AU - Doherty, Meg Caroline

AU - Benzaken, Adele Schwartz

PY - 2019/3/1

Y1 - 2019/3/1

N2 - In 2017, the Ministry of Health Brazilian started using dolutegravir (DTG) 50 mg to all people living with HIV who began antiretroviral therapy (ART) or rescue regimens. Although DTG is thought to have better tolerability levels and a lower possibility of causing adverse reactions, it is necessary to continuously evaluate the safety profile of the drug in the population. Therefore, an active pharmacovigilance project for DTG was implemented. The objective of this study was to describe the Brazilian experience of implementing pharmacovigilance and the results obtained during the period between April and December 2017.Active pharmacovigilance was implemented through patient interviews and an online questionnaire developed in the Medication Logistics Control System (SICLOM).Of the total number of people on DTG in Brazil (79,742) 90.33% participated in the project, and 2.24% of those who participated reported adverse reactions to the drug; of those who reported adverse reactions, 73.86% were on first-line ART regimens, and 26.13% were on third-line regimens. The mean age of the patients who had adverse reactions to DTG was 39 years; 68.79% were male, and 31.21% were female. Of the adverse reactions reported, 50.39% were considered persistent. The 3 most frequent reactions were nausea (13.34%), diarrhea (9.83%), and headaches (9.23%).The Brazilian experience with this project has been deemed successful by federal and local managers, and the online tool to collect data has proved to be an important strategy for the pharmacovigilance of DTG as well as that of other drugs.

AB - In 2017, the Ministry of Health Brazilian started using dolutegravir (DTG) 50 mg to all people living with HIV who began antiretroviral therapy (ART) or rescue regimens. Although DTG is thought to have better tolerability levels and a lower possibility of causing adverse reactions, it is necessary to continuously evaluate the safety profile of the drug in the population. Therefore, an active pharmacovigilance project for DTG was implemented. The objective of this study was to describe the Brazilian experience of implementing pharmacovigilance and the results obtained during the period between April and December 2017.Active pharmacovigilance was implemented through patient interviews and an online questionnaire developed in the Medication Logistics Control System (SICLOM).Of the total number of people on DTG in Brazil (79,742) 90.33% participated in the project, and 2.24% of those who participated reported adverse reactions to the drug; of those who reported adverse reactions, 73.86% were on first-line ART regimens, and 26.13% were on third-line regimens. The mean age of the patients who had adverse reactions to DTG was 39 years; 68.79% were male, and 31.21% were female. Of the adverse reactions reported, 50.39% were considered persistent. The 3 most frequent reactions were nausea (13.34%), diarrhea (9.83%), and headaches (9.23%).The Brazilian experience with this project has been deemed successful by federal and local managers, and the online tool to collect data has proved to be an important strategy for the pharmacovigilance of DTG as well as that of other drugs.

UR - http://www.scopus.com/inward/record.url?scp=85062704362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062704362&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000014828

DO - 10.1097/MD.0000000000014828

M3 - Article

VL - 98

SP - e14828

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 10

ER -